🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

84 results for “Alnylam Netherlands B.V.” Clear

  1. ALN-6400

    Alnylam Netherlands B.V.

    Von Willebrand Disease (VWD)

    phase 2 small molecule active

    1 trial

  2. ALN-6400

    Alnylam Netherlands B.V.

    Hereditary Hemorrhagic Telangiectasia

    phase 2 small molecule active

    1 trial

  3. ALN-AAT02

    Alnylam Netherlands B.V.

    ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

    phase 2 small molecule terminated

    1 trial

  4. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule active

    1 trial

  5. ALN-CC5

    Alnylam Netherlands B.V.

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

  6. ALN-KHK

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule terminated

    1 trial

  7. ALN-RSV01

    Alnylam Netherlands B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    3 trials

  8. ALN-TTR02 (patisiran) administered by intravenous (IV) infusion

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  9. ALN-TTRSC (revusiran) for subcutaneous administration

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  10. ALN-XDH

    Alnylam Netherlands B.V.

    Gout

    phase 2 small molecule terminated

    1 trial

  11. Givosiran

    Alnylam Netherlands B.V.

    Acute Intermittent Porphyria

    phase 2 small molecule completed

    1 trial

  12. Indapamide

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule completed

    1 trial

  13. Lumasiran

    Alnylam Netherlands B.V.

    Primary Hyperoxaluria Type 1 (PH1)

    phase 2 small molecule completed

    1 trial

  14. Lumasiran

    Alnylam Netherlands B.V.

    Recurrent Calcium Oxalate Kidney Stone Disease

    phase 2 small molecule terminated

    1 trial

  15. Lumasiran

    Alnylam Netherlands B.V.

    Haemodialysis

    phase 2 small molecule active

    1 trial

  16. Lumasiran

    Alnylam Netherlands B.V.

    PH1

    phase 2 small molecule completed

    1 trial

  17. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 small molecule active

    1 trial

  18. Patisiran

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  19. Phosphate buffered saline for SC administration

    Alnylam Netherlands B.V.

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  20. Placebo

    Alnylam Netherlands B.V.

    Hypertension

    phase 2 small molecule completed

    1 trial

  21. Placebo

    Alnylam Netherlands B.V.

    IgA Nephropathy (IgAN)

    phase 2 small molecule terminated

    1 trial

  22. Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy

    phase 2 small molecule active

    1 trial

  23. Revusiran

    Alnylam Netherlands B.V.

    Transthyretin (TTR)-Mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

  24. Revusiran (ALN-TTRSC)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources